Science Exchange connects pharmaceutical companies with early-stage biotech firms, facilitating advancements in cancer biology and other areas. The application of artificial intelligence in the biological sector is leading to innovations in predicting drug efficacy and toxicity during the preclinical stage, which helps avoid clinical failures.